Results for: Quiz 1z0-076 - Oracle Database 19c: Data Guard Administration Marvelous Reliable Exam Sample 🔡 Download ▷ 1z0-076 ◁ for free by simply searching on “ www.pdfvce.com ” 😙1z0-076 Valid Test Tips

Too few patients considered candidates for treatment optimization

October 8, 2015

…44.8 years; mean MS duration was 9.6 years; and median EDSS score was 2.0. Data were complete for 1,594 patients. Overall, 810 (50.8%) had evidence of ongoing disease activity, defined as >1 relapse or EDSS progression (>0.5 points) or increased MRI activity in the preceding 24 months. Neurologists rated their patients as improved in 2.3%, stable in 64.8%, or worsened in 31.9%. As a result, a switch to another disease-modifying therapy was conside…

Current DMTs – an overview of observational studies

October 8, 2015

…y of real-world studies of current DMT use in clinical practice. Interferon-beta-1a s.c.: The Centre hospitalier de l’Université de Montréal (CHUM) surveyed 296 MS patients on IFNbeta-1a for at least two years and untreated patients about cognition, quality of life and employment (Rouleau et al. ECTRIMS 2015; abstract P313). QoL was assessed with the MSQoL-54; cognition was evaluated with MACFIMS. Mean disease duration was 15 years for the IFNbeta…

Sublingual apomorphine in PD: phase II results

September 2, 2015

…an change from baseline in MDS-UPDRS Part III score was -15 at 45 minutes (-35%), and -9 at 90 minutes (-24%). A majority of subjects responded to the lowest doses (10-15 mg). The most common adverse effects were dizziness (36.8%), somnolence (31.6%), nausea (21.1%) and yawning (15.8%) (Isaacson et al. EAN 2015; abstract P215). There were two serious adverse events (somnolence, dysphagia). Most adverse events were mild. The phase III CTH-300 trial…

Sequencing MS therapies: 2 studies

August 19, 2015

…ld need to be determined. Comment Dr. Daniel Selchen: The size of the above-noted data sets is an illustration of the problems we face in terms of trying to develop safe and effective strategies for switching treatments in aggressive disease. This is an area where properly designed phase IV trials could be very helpful, at least in terms of efficacy data. Safety – particularly with regard to PML risk – is going to take years of observation and car…

Does psoriasis improve MS outcomes?

August 19, 2015

…Peripheral blood mononuclear cell (PBMC) gene expression was compared in MS-P, MS-only and psoriasis-only patients versus healthy controls. MS-P patients demonstrated a decreased expression of inflammatory and proliferative pathways compared to MS-only patients. For example, MS-P patients had decreased expression of mTOR (mammalian target of rapamycin), which is involved in T cell activation and proliferation, and inhibition of regulatory T cell d…